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Abstract
The anatomical and histological complexity of the parasellar 
region as well as the presence of embryonic remnants deter-
mine the huge diversity of parasellar neoplasms. Some of 
them are only located in the parasellar region, whereas 
others can occur elsewhere, within or outside the central 
nervous system. Their spectrum ranges from histologically 
benign and low-grade malignant to high-grade malignant 
tumours. Although rare, metastases can pose differential di-
agnostic dilemmas. The severity of the clinical picture, the 
challenges of surgery and the risk of adverse sequelae re-
lated to surgery or radiotherapy make parasellar tumours in-
teresting entities for the clinicians irrespective of their histo-
logical malignancy grade. Due to the different cell origins of 
parasellar tumours, the World Health Organization classifica-
tion system does not categorise them as a distinct group. 
Detailed criteria for classification and malignancy grading 
are presented in the classification systems covering central 
nervous system tumours, haematological malignancies and 
tumours of the soft tissue and bone. In the last few years, 
molecular genetic features have been integrated into the di-
agnosis of several types of the parasellar tumours enhancing 
diagnostic accuracy and providing information of the value 
for targeting therapies. In this review, we will present histo-
pathological and molecular genetic features, updated clas-
sification criteria and recent advances in the diagnostics and 
rationale for novel pharmacological therapies of selected 
types of parasellar neoplasms. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
The parasellar region is an anatomically complex area 
bordering the sella turcica and containing crossroads of 
many vital structures. The broad landscape of neoplastic 
lesions in the parasellar region is determined by the pres-
ence of numerous and histologically heterogenous struc-
tures, as well as of embryonic remnants. With the excep-
tion of craniopharyngioma which very rarely arises outside 
this region, all other parasellar tumours can occur else-
where, within or outside the central nervous system (CNS).
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
the online version of the article only. Usage and distribution for com-
mercial purposes requires written permission.
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In surgical series, the most frequent neoplasms in the 
parasellar region are invasive pituitary neuroendocrine 
tumours. All other neoplasms are rare and comprise 
about 9% of the tumours of different cell origin and his-
tological malignancy grade [1, 2]. Metastases are uncom-
mon but can occur even a long time after the diagnosis of 
the primary tumour and need to be included in the dif-
ferential diagnosis [2, 3]. Originating from different cell 
types, the parasellar tumours are classified according to 
the World Health Organization (WHO) classification 
systems of different organs and tissues [4–7] (Table 1). 
Parasellar tumours can affect vital anatomical structures, 
causing a broad spectrum of manifestations, the type and 
severity of which depend on size, location, biological be-
haviour of the tumour and age at diagnosis [1, 8, 9]. These 
complex clinical aspects make the parasellar tumours 
challenging even when they have benign histological fea-
tures. Surgery and/or radiotherapy of parasellar tumours 
can be associated with a high risk of acute and long-term 
endocrine, neurological, psychological and cognitive 
complications [2, 10, 11]. This necessitates the introduc-
tion of novel pharmacological therapies and definition of 
the predictive markers. 
In this paper, we will summarise the literature covering 
histopathological and molecular genetic aspects of select-
ed parasellar neoplasms. Given the limitations in the 
length of this mini review, we will focus on tumours oc-
curring almost exclusively in the parasellar region, those 
showing a predisposition for the parasellar area and a few 
tumour types that have only rarely been described in this 
location. Despite their clinical significance, other lesions 
usually covered in reviews describing central nervous and 
soft tissue tumours (e.g., meningiomas) will not be includ-
ed. Recent advances in the diagnostics and rationales for 
novel pharmacological therapies will also be presented.
Parasellar Region: Anatomical Considerations
The sellar region resides at the centre of the cranial 
base on the sphenoid bone with complex neural and vas-
cular associations. The sella turcica (Turkish saddle) lies 
in the centre of the sphenoid bone containing the pitu-
itary gland. Anteriorly is the tuberculum sellae and pos-
teriorly the dorsum sellae and clivus. Inferior to the fossa 
is the sphenoid sinus. Below and behind the sella turcica 
is the sphenoid sinus that extends posteriorly to the cli-
vus. Above, the sella is covered by the diaphragma sellae 
as a roof where the infundibulum of the pituitary gland 
passes through up to the hypothalamus (Fig. 1).
The parasellar region is a part of the middle fossa, be-
tween the sella and the temporal fossa. It can be defined 
as the area surrounding the sella turcica and includes su-
prasellar cistern, cavernous sinuses, hypothalamus and 
anterior inferior part of the third ventricle. 
The suprasellar cistern is a cerebrospinal fluid-filled 
space shaped like a pentagon when viewed from above 
containing the circle of Willis. The infundibulum passes 
in the centre surrounded anteriorly by the optic chiasm 
and laterally by the uncus of the temporal lobes. 
Cavernous sinuses lie lateral to the pituitary gland 
where the lateral part of the body of the sphenoid forms 
a
c b
Fig. 1. Anatomical relationships. a Coronal 
section of the parasellar region. PG, pitu-
itary gland; ICA, internal carotid artery; SS, 
sphenoid sinus; CS, cavernous sinus; CN, 
cranial nerve; V1, ophthalmic branch; V2, 
maxillary branch; NP, nasopharynx; TL, 
temporal lobe; I, infundibulum. b Inferior 
view. ACA, anterior cerebral artery; ON, 
optic nerve; OA, ophthalmic artery; C4-
OP, cavernous segment of carotid artery, 
the ophthalmic part; AL, anterior lobe of 
the pituitary; PL, posterior lobe of the pitu-
itary; TC, tuber cinereum; ACh.A, anterior 
choroidal artery; PCo. A, posterior com-
municating artery. c Sagittal section of the 
parasellar region. BA, basilar artery; C, cli-
vus. Figure 1 is authored by Dr. Elham Ros-
tami.
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Table 1. Types of parasellar tumours
Tissue of the origin Tumour type
Embryonic remnants of  
Rathke’s pouch* Craniopharyngioma*– Adamantinomatous
– Papillary
Notochordal remnants* Notochordal tumours*
– Benign notochordal cell tumour*
– Chordoma* 
⚪ Chordoma NOS 
⚪ Chondroid chordoma
⚪ Dedifferentiated chordoma
Neural crest remnants* Paraganglioma*
Fibroblastic cell* Solitary fibrous tumour/haemangiopericytoma*
Fibroblast/monocyte/osteoclast* Giant cell tumour of the bone*
Germ cells* Germinoma*
Yolk sac tumour*
Embryonal cell carcinoma*
Choriocarcinoma*
Teratoma*
Mixed germ cell tumour*
Lymphocytic neoplasms* Diffuse large B-cell lymphoma of the CNS*
Histiocytic neoplasms* Langerhans cell histiocytosis*
Disseminated juvenile xanthogranuloma*
Erdheim-Chester disease*
Arachnoidea Meningioma
Grade I
– Meningothelial
– Fibrous
– Transitional
– Other histological types
Grade II
– Atypical
– Chordoid
– Clear cell
Grade III
– Anaplastic
– Rhabdoid
– Papillary
Chondroid tissue Chondroma
Chondrosarcoma
Bone Osteoma 
Osteosarcoma
Adipose tissue Lipoma
Liposarcoma
Smooth muscle Leiomyoma
Leiomyosarcoma
Striated muscle Rhabdomyosarcoma
Glia* Pilocytic astrocytoma*
Pilomyxoid astrocytoma*
Chordoid glioma of the third ventricle*
Endothelium Haemangioma
Unknown Atypical teratoid/rhabdoid tumour
Schwann cells Schwannoma
Malignant peripheral nerve sheet tumour* Selected tumour types covered by the review. NOS, not otherwise specified; CNS, central nervous system.
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the inferior part of the medial wall of the cavernous sinus, 
extending from the petrous apex to the superior orbital 
fissure.
The cavernous sinus is encapsulated by two layers of 
the dura. The oculomotor nerve (cranial nerve, CN III), 
trochlear nerve (CN IV), ophthalmic (V1) and maxillary 
(V2) branches of the trigeminal nerve (CN V) pass through 
the later wall of the cavernous sinus while the abducens 
nerve (CN VI) and carotid artery pass through the cav-
ernous sinus. 
The parasellar area is considered to be the smallest area 
of the skull base with the highest concentration of impor-
tant neural and vascular structures making any neoplasm 
in this area potentially leading to the neurological deficits 
with life-threatening complications [12, 13].
Craniopharyngioma
Craniopharyngioma is a histologically benign, al-
though invasively growing, cystic and/or solid tumour 
originating from the embryonic remnants of Rathke’s 
pouch [4]. This origin was proposed at the beginning of 
the 20th century based on the histological similarities be-
tween Rathke’s pouch and craniopharyngiomas [14]. 
This hypothesis has been further supported by the recent 
identification of molecular markers of Rathke’s pouch 
precursors in murine and human craniopharyngiomas 
[15, 16]. Craniopharyngiomas are almost exclusively lo-
cated in the sellar and suprasellar regions [17]. The cer-
ebellopontine angle is the most frequent location among 
uncommon cases of extrasellar craniopharyngiomas 
[18]. 
Craniopharyngioma occurs in two morphologically 
distinct variants. Adamantinomatous craniopharyngio-
ma (ACP) is composed of squamous epithelium with fo-
cally looser “stellate reticulum,” palisading of the basal 
cells and accumulation of degenerative, “wet keratin” [4] 
(Fig. 2a). Papillary craniopharyngioma (PCP) consists of 
non-keratinising squamous epithelium covering papil-
lary fibrovascular cores [4] (Fig.  2d). Rarely, ACP and 
PCP coexist in the same lesion [19, 20]. ACP is the pre-
dominant subtype in childhood onset disease but may de-
velop at all ages, whereas PCP is almost exclusively found 
in adults [4]. Craniopharyngioma has a distinct micro-
scopic morphology. Differential diagnostic difficulties as-
sociated with other epithelial tumours (e.g., metastases) 
that can be rarely encountered in cases with sparse patho-
logical material, are usually resolved by a multidisci-
plinary approach correlating histopathology, MRI find-
ings and clinical characteristics, such as patient age or his-
tory of malignancy in other organs.
The molecular mechanisms behind the two histologi-
cal variants of craniopharyngiomas have recently been 
clarified. ACP is characterised by mutations in the CTN-
NB1 gene, encoding β-catenin, which subsequently lead 
to aberrant nuclear translocation of this protein as dem-
onstrated by immunohistochemistry in a subset of tu-
mour cells forming epithelial whorls [21] (Fig. 2c). Near-
ly all PCPs are driven by a BRAFV600E mutation that 
constitutively activates the MAPK/ERK signalling path-
way [22]. Mutated BRAFV600E is expressed in epithelial 
neoplastic cells and can be demonstrated by using a 
monoclonal VE1 antibody (Fig. 2e) [23]. However, posi-
tive immunolabelling with the VE1 antibody without de-
tectable BRAFV600E mutation has been demonstrated in 
the anterior pituitary gland, other endocrine organs and 
a subset of pituitary neuroendocrine tumours [24, 25]. 
Therefore, confirmation of the mutation by genetic anal-
ysis is recommended, particularly in patients who are 
candidates for BRAF-targeting therapy.
BRAFV600E inhibitors alone or in combination with 
MAPK/ERK inhibitors have been successfully used re-
cently in PCPs [26–31]. On the other hand, drugs target-
ing β-catenin and its downstream MAPK pathway have 
been used only in in vitro studies, and their value in the 
management of ACP requires assessment in a clinical tri-
al [32, 33]. Recently, the programmed cell death protein 
1 and programmed cell ligand-1 (PD-1/PD-L1) have been 
demonstrated in epithelial neoplastic cells and immune 
cells of both ACP and PCP [34, 35] opening a new pos-
sible avenue for immune-mediating therapy of cranio-
pharyngiomas.
Chordoma
Chordomas are malignant tumours arising from the 
embryonic notochordal remnants typically affecting the 
most extreme part of the axial skeleton, clivus and lum-
bosacral vertebral column. They are surgically challeng-
ing to remove and may metastasise in up to 40% of cases, 
more commonly the spinal than the skull base chordomas 
[7]. Chordomas are composed of large, vacuolated “phy-
saliphorous cells” frequently growing in a trabecular pat-
tern surrounded by a myxoid matrix (Fig. 3a, b) [7]. Sim-
ilar to the embryonic notochord, the neoplastic cells of 
chordoma express both epithelial (cytokeratin) and neu-
ronal (S-100 protein) markers, as well as brachyury, a T-
gene encoded transcription factor that plays a pivotal role 
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in the notochord differentiation (Fig. 3c–e) [36, 37]. Al-
though rarely expressed in other tumours, brachyury is a 
specific marker valuable in the pathological differen-
tiation of chordoma from chondroma, chondrosarco- 
ma, chordoid meningioma and carcinomas [38]. Germ-
line duplications of T gene encoding brachyury are asso-
ciated with familial predisposition to chordoma [39]. 
Apart from the most frequent conventional chordoma 
or chordoma not otherwise specified, the WHO classifi-
cation defines two additional rare subtypes [7], the chon-
droid chordoma and the dedifferentiated chordoma. In 
chondroid chordoma, the myxoid matrix resembles hya-
line cartilaginous tumour. This subtype has no prognos-
tic value but needs to be discriminated from chondroma 
and chondrosarcoma based on morphology, brachyury 
expression in chordoma and evidence of isocitrate dehy-
drogenase 1 or 2 (IDH1/2) mutations in a subset of chon-
dromas and chondrosarcomas [40]. Dedifferentiated 
chordoma is a biphasic tumour with a conventional 
brachyury-positive chordoma component and a dediffer-
entiated, spindle cell sarcoma component which has loss 
of brachyury [7]. In 5 out of 6 recently reviewed cases, this 
high-grade malignant subtype developed through dedif-
ferentiation secondary to radiotherapy or after incom-
plete surgical removal of a conventional chordoma [41]. 
Not included in the current WHO classification is a rare 
a b c
d e f
Fig. 2. Craniopharyngioma. Adamantinomatous type (upper row) characterised by: typical epithelial features 
with “wet keratin” and “stellate reticulum” (a, HE, ×100); lack of BRAFV600E immunolabelling (b, ×100); a 
nuclear translocation of β-catenin in tumour cells forming epithelial whorls (c, ×200). Papillary craniopharyn-
gioma (lower row) characterised by: papillary projections of non-keratinising squamous epithelium (d, HE, 
×100); expression of BRAFV600E (e, ×100) and membranous β-catenin positivity (f, ×200).
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paediatric poorly differentiated chordoma of the clivus 
characterised by loss of SMARCB1 (INI1) and poor prog-
nosis [42, 43]. Brachyury expression is valuable to differ-
entiate this variant from INI1-negative atypical teratoid 
rhabdoid tumour that has exceptionally been reported in 
the sellar region [42, 44–46].
Benign notochordal cell tumour has a very indolent 
course and should not be misdiagnosed as a chordoma. It 
is composed of adipocyte-like, brachyury-positive cells 
and lacks a myxoid matrix. Despite occasional coexistence 
in the same lesion, there is no evidence that benign noto-
chordal cell tumour is a precursor of chordoma [7, 47–49].
Mutations in the PI3K/AKT/TSC1/TSC2/mTOR sig-
nalling pathway in chordomas could be potential targets 
of mTOR inhibitors [50]. Nonetheless, current data sug-
gest suboptimal response to these agents [51]. Further-
more, initial results with immune-check point inhibitors 
and brachyury-targeting therapy have not been encour-
aging [52]. Tazemetostat, an inhibitor of EZH2 protein 
which is upregulated in tumours characterised by 
SMARCB1 loss, is under a clinical trial and has shown 
promising results in paediatric patients with poorly dif-
ferentiated chordomas [51].
Paraganglioma
Paragangliomas are neuroendocrine neoplasms, usu-
ally encapsulated and benign. It is postulated that they 
arise from remnant neural crest cells which are diffusely 
dispersed or are associated with segmental or collateral 
autonomic ganglia (paraganglia). In the CNS, paragan-
gliomas primarily affect the cauda equina/filum termi-
nale and jugulotympanic regions [4]. Less than 20 cases 
a b
c d e
Fig. 3. Chordoma not otherwise specified demonstrating “physaliphorous” tumour cells arranged in trabecules 
(a, HE, ×200), rich myxoid matrix surrounding the tumour cells (b, Alcian blue/PAS, ×200), cytokeratin AE1/
AE3 (c, ×200), S-100 (d, ×200) and nuclear brachyury expression (e, ×200).
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of primary sellar/parasellar paraganglioma have been re-
ported and recently reviewed; none of them had evidence 
of catecholamine secretion [53, 54]. 
Although classified as histologically benign WHO 
grade I tumours, paragangliomas may demonstrate inva-
sive growth and in up to 20% of cases, there are even dis-
tant metastases [4]. Distant metastases have not been re-
ported as yet in parasellar paragangliomas [53]. Genetic 
analysis for identifying familiar cases is needed, and its 
results will determine further monitoring. 
Histologically, paragangliomas are composed of syn-
aptophysin- and chromogranin A-positive neuroendo-
crine chief cells that form a typical lobular, “zellballen” 
pattern emphasised by peripheral S-100- and glial fibril-
lary acidic protein-immunolabelled sustentacular cells. 
Expression of cytokeratin may vary and be absent in pri-
mary sellar paragangliomas [53]. Mitotic figures and ne-
crosis are rare [4]. There are no histological parameters 
reliably predicting the risk for invasive growth or meta-
static potential. In cases without typical morphology, 
positive immunolabelling for tyrosine hydroxylase and 
lack of organ-specific transcription factors can be helpful 
to differentiate paraganglioma from pituitary neuroen-
docrine tumours or metastases of neuroendocrine tu-
mours from other locations.
Up to 50% of adult paragangliomas and more than 
80% of paediatric ones are associated with germline mu-
tations [4], most frequently in one of the succinate dehy-
drogenase (SDH) genes: SDHA, SDHB, SDHC, SDHD, 
SDHAF2 [55–59]. In addition to family history, early on-
set, multiple tumour occurrence and association with 
non-paraganglial tumours should raise suspicion for ge-
netic predisposition [60]. Immunohistochemistry on sec-
tions from formalin-fixed paraffin-embedded tissue is a 
reliable method to detect SDHx mutations [61, 62], with 
loss of SDHB revealing mutations in different SDH genes 
[61]. Recently, somatic ATRX mutations, which can be 
suspected on the basis of the lack of ATRX in the tumour 
a b
c d
Fig. 4. Haemangiopericytoma/solitary fibrous tumour. a Solitary fibrous tumour phenotype characterised by 
spindle cells arranged in fascicles separated by thick collagenous bands. HE, ×200. b Haemangiopericytoma phe-
notype with haphazard growth pattern of cells with round to ovoid nuclei and thin-walled branching vessels. HE, 
×200. c, d CD34 expression (c, ×200) and nuclear expression of STAT6 (d, ×200).
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cells, have been reported and strongly associated with a 
risk for metastatic paragangliomas [63, 64]. Somatic mu-
tations in isocitrate dehydrogenase are extremely uncom-
mon in paragangliomas [65] and can coexist with ATRX 
mutations [66].
Haemangiopericytoma/Solitary Fibrous Tumour
Haemangiopericytoma is a mesenchymal tumour of 
fibroblastic type. It represents a histological spectrum of 
neoplasms previously classified separately as meningeal 
solitary fibrous tumour (SFT) and haemangiopericytoma 
(HPC) [4]. In the CNS, HPC and SFT are usually, but not 
always, connected to the cranial or spinal dura [67]. The 
sellar/parasellar region is an uncommon location with 
less than 20 cases reported until now in sporadic case re-
ports that are seldomly comprehensively reviewed [68].
A distinct molecular feature unifying SFT and HPC 
into one group is a fusion of NAB2 and STAT6 genes [4, 
69, 70] which results in nuclear translocation of STAT6 
protein; this can be detected by immunohistochemistry 
and represents a key diagnostic feature of SFT/HPC [71]. 
Nuclear STAT6 expression is also a useful marker for the 
differential diagnosis towards fibrous meningioma or sel-
lar schwannoma that can be particularly challenging 
when the surgical material is sparse and the morphology 
not typical.
Morphologically, SFTs are tumours composed of spin-
dle cells growing in fascicles separated by thick collage-
nous bands. HPCs are characterised by haphazard ar-
rangement of cells with spindle-shaped to oval nuclei sur-
rounded by a rich and delicate reticulin network and 
characteristic staghorn vascular pattern. Both morpho-
logical types, besides nuclear STAT6 positivity, express 
typically vimentin and CD34 (Fig. 4) [4]. Several studies 
indicate that the morphological phenotype depends on 
the type of NAB2/STAT6 fusion [72–75].
SFT is a benign WHO grade I tumour, whereas the 
HPC phenotype demonstrates more aggressive behav-
a b
c d
Fig. 5. Giant cell tumour of the bone. a Neoplastic mononuclear cells admixed with macrophages and osteoclast-
like giant cells. HE, ×200. b Tumour cells infiltrating extracranial muscle. HE, ×200. c CD68-positive reactive 
cells. ×400. d CD163 immunolabelling of neoplastic cells. ×400.
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iour with a relatively high rate of recurrence and risk of 
metastasis giving ground to its higher malignancy grade 
compared to the SFT. The single histological criterion to 
differentiate between WHO grade II and grade III HPC 
is the mitotic count with a cut-off level of 5 mitoses per 
10 high-power field [4]. In a recent study, a three-tiered 
system including both mitotic count and necrosis seemed 
to provide the most accurate prognostic stratification 
within this tumour family [75].
Giant Cell Tumour of Bone
Giant cell tumour (GCT) of bone is a benign but lo-
cally aggressive primary bone neoplasm that typically af-
fects the epiphyses of long bones. In uncommon cases of 
skull involvement, GCT shows a predilection for tempo-
ral and sphenoid bone [76]. Rare primary malignancies 
and malignancy secondary to radiotherapy in GCT [77, 
78] could be, at least partially, explained by p53 mutations 
[79, 80].
Histologically, the GCT is composed of a proliferation 
of neoplastic mononuclear cells admixed with numerous 
macrophages and large reactive osteoclast-like giant cells. 
The neoplastic cells express CD163, a macrophage and 
monocyte activation marker, and lack CD68, a classical 
macrophage marker expressed in reactive macrophages 
and osteoclast-like giant cells of the GCT [7] (Fig.  5). 
More than 90% of GCTs are characterised by a distinct 
H3.3 histone mutation in H3F3A [81] which is used for 
the differentiation from the other giant cell, osteoclast-
rich bone tumours and chondroblastomas, especially in 
scarce fine-needle biopsy specimens [82, 83]. Due to de-
calcification protocols applied to the bone tumour speci-
a b
c d e
Fig. 6. Germinoma characterised by: sheets of uniform rounded cells with clear cytoplasm (a, HE, ×400); focal 
lymphocytic infiltration (b, HE, ×400); membranous D2-40 expression (c, ×400); nuclear Oct 3/4 (d, ×400) and 
membranous CD117 (e, ×400) immunolabelling.
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mens, molecular pyrosequencing-based techniques seem 
to be more reliable than immunohistochemistry in the 
identification of H3F3A mutations [84].
Germ Cell Tumours
Intracranial germ cell tumours arise along the cranial 
midline axis, slightly less frequently in the suprasellar 
than in the pineal region, with predilection for children 
and young adult males [4]. Simultaneous occurrence of 
suprasellar and pineal germ cell tumour has been desig-
nated as “bifocal germ cell tumour” [85]. The germ cell 
tumours, except benign teratomas, are malignant and can 
easily metastasise through the cerebrospinal fluid, e.g. 
“drop metastases.” In the CNS, germ cell tumours repre-
sent the morphological, immunophenotypic and genetic 
homologues of gonadal and other extraneuraxial germ 
cell neoplasms [4]. The histogenesis of these tumours in 
the CNS is unclear. An origin from the primordial germ 
cells remaining in the neuraxial midline due to aberrant 
migration to the gonadal ridges or from the native neural 
stem cells of embryonic pluripotent type has been sug-
gested [86–89]. A significantly higher incidence in east-
ern Asia which persists even in ancestries settled in the 
other parts of the world suggests the implication of ge-
netic factors [4, 90].
The WHO classification system recognises 5 histolog-
ical types of germ cell tumours: germinomas, embryonal 
carcinoma, yolk-sac tumour, choriocarcinoma and tera-
toma. Mixed types with the presence of different tumour 
components are not uncommon [4]. Germ cell tumours 
can be divided into two risk groups: germinomas and 
non-germinomas, with significantly better prognosis af-
ter radio- and chemotherapy for the former group [91]. 
The most frequent subtype, germinoma is characterised 
by sheets of rounded CD117, D2-40, OCT4 and NANOG-
positive cells surrounded by lymphocytes, dominantly of 
T-cell phenotype (Fig. 6). Lymphocytic infiltration, some-
times with formation of germinal centres, can mask the 
typical morphology and represent a challenging differen-
tial diagnosis versus chronic inflammatory lesion or hae-
matological malignancies, especially in scarce specimens. 
In such cases, a detailed clinical, radiological and patho-
logical correlation is highly recommended. Other histo-
logical subtypes are very rare in the CNS as a primary 
location and show the histological pattern seen in the go-
nadal presentation.
Recent molecular investigations of germ cell tumours 
revealed mutations in the MAPK pathway frequently as-
sociated with male gender [91]. Recurrent mutations in 
the mTOR pathway in intracranial germ cell tumours 
have emerged as potential therapeutic targets [92]. Rich 
lymphocytic infiltration in germinomas and expression 
of PD-1 and PDL-1 on the inflammatory cells within ger-
minomas may potentially be targeted by immune check 
point inhibitors [93].
Haematopoietic and Lymphoid Tumours
Even though lymphomas and histiocytic cell neo-
plasms are rarely observed in the CNS, as a solitary lesion 
or in the form of the disseminated disease, the parasellar 
region could also be affected.
Similarly, to the CNS lymphomas in general, rare para-
sellar lymphomas belong to diffuse large B-cell lympho-
mas [94]. 
Several types of histiocytic disorders, such as Langer-
hans cell histiocytosis, disseminated juvenile xanthogran-
uloma and Erdheim-Chester disease, may have predilec-
tion for the parasellar region. Morphological, immuno-
histochemical and molecular genetic features of these 
tumours are in detail presented elsewhere [6]. Although 
considered as reactive in the past, the majority of histio-
cytic lesions in the CNS including the parasellar region 
represent true monoclonal neoplasms [6] that need to be 
differentiated from the secondary inflammatory lesions 
[95].
Glial Tumours
Even though glial tumours of all types could be local-
ised in the parasellar space, pilocytic astrocytoma, pilo-
myxoid astrocytoma and chordoid glioma of the third 
ventricle show predilection for this region [4]. These can 
be differentiated from other tumour types based on their 
morphology and on the expression of glial fibrillary acid-
ic protein that confirms the glial origin of the tumour 
cells.
The optic tract and hypothalamus comprise preferable 
supratentorial location for pilocytic astrocytoma. Pilocyt-
ic astrocytoma involving the optic nerve is a hallmark of 
neurofibromatosis type 1 [4]. A majority of pilocytic as-
trocytomas contain a KIAA1549-BRAF fusion gene [96]. 
BRAFV600E mutation is, however, associated with extra-
cerebellar tumour location in a subset of patients [97]. 
Although in general slowly growing tumours correspond-
ing to WHO grade 1, pilocytic astrocytomas in parasellar 
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location may not be amenable to gross total resection, 
which increases a risk of recurrence and progress [4]. 
Pilomyxoid astrocytoma is a variant of pilocytic astro-
cytoma of uncertain malignancy grade preferentially af-
fecting the hypothalamic/chiasmatic region in young 
children [4]. 
Chordoid glioma of the third ventricle is a rare, WHO 
grade II neoplasm of adult patients with favourable prog-
nosis when totally resected [4]. However, the tumour is 
mostly attached or invades the hypothalamus; conse-
quently, only subtotal resection has been reported. A re-
cent study defined PRKCA mutation as a recurrently mu-
tated oncogene in pilomyxoid astrocytoma, which may 
have potential therapeutic implications [98]. 
Conclusion
A wide heterogeneity of parasellar neoplasms de-
mands a huge experience in neuropathology in order to 
cover this fascinating field and avoid pitfalls in histopath-
ological diagnostics. Integration of the molecular genetic 
mechanisms in the evolving WHO tumour classification 
increases diagnostic accuracy and enables new targeted 
pharmacotherapies giving hope for an optimised impact 
on the patients’ prognosis and outcome. A multidisci-
plinary approach is required in order to overcome chal-
lenges in the diagnostics and treatment of patients with 
parasellar neoplasms.
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